{"id":554526,"date":"2021-07-26T23:14:01","date_gmt":"2021-07-26T23:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=554526"},"modified":"2021-07-26T23:14:01","modified_gmt":"2021-07-26T23:14:01","slug":"lichen-planus-treatment-market-to-derive-enormous-growth-from-the-expected-launch-of-emerging-therapies-in-the-forecast-period-202030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lichen-planus-treatment-market-to-derive-enormous-growth-from-the-expected-launch-of-emerging-therapies-in-the-forecast-period-202030_554526.html","title":{"rendered":"Lichen Planus Treatment Market to Derive Enormous Growth from the Expected launch of Emerging Therapies in the Forecast Period (2020-30)"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1627277922.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Lichen Planus Treatment Market to Derive Enormous Growth from the Expected launch of Emerging Therapies in the Forecast Period (2020-30)\" src=\"https:\/\/www.abnewswire.com\/uploads\/1627277922.png\" alt=\"Lichen Planus Treatment Market to Derive Enormous Growth from the Expected launch of Emerging Therapies in the Forecast Period (2020-30)\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Lichen Planus Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The total Lichen Planus market size will include both the market size of upcoming therapies like Rivelin-clobetasoL, Valchlor (mechlorethamine), KPL-716, and others, as well as the market size of current Lichen Planus treatment regimens in the 7MM.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/f0446d618520b0e71a50e5b153157479.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&rsquo;s&nbsp;<\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lichen-planus-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Lichen Planus market report<\/a><\/strong><span> provides an in-depth understanding of the Lichen Planus, historical and forecasted epidemiology, as well as Lichen Planus market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also examines current Lichen Planus treatment practices\/algorithms, Lichen Planus market drivers, Lichen Planus market barriers, and unmet medical needs to identify and evaluate the market&#8217;s underlying potential.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Highlights from the Lichen Planus Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to the National Organization for Rare Disorders (NORD), Lichen Planus affects less than <\/span><strong>1% <\/strong><span>of the global population.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to the Human Phenotype Ontology (HPO) Database, baldness, hyperkeratosis, lichenification, and papule occur in <\/span><span>80-99 percent <\/span><span>of Lichen Planus patients, while aberrant fingernail morphology occurs in <\/span><span><strong>30-79 percent<\/strong>.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Several key pharmaceutical companies such as <\/span><strong>AFYX Therapeutics, Novartis, Actellion, Kiniksa Pharmaceuticals, <\/strong><span>and others are developing novel therapies to boost the Lichen Planus treatment outlook.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span><strong>Novartis<\/strong> <\/span><span>is developing <\/span><strong>AIN457 (Cosentyx)<\/strong><span>, a IL17A (Anti-interleukin-17 monoclonal antibody) inhibitor. The drug is currently in phase II clinical development for the treatment of Lichen Planus.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Some of the other promising therapies which are in the pipeline for Lichen Planus treatment include <\/span><strong>Rivelin-clobetasoL (AFYX Therapeutics), Valchlor (mechlorethamine) (Actellion), and KPL-716 (Kiniksa Pharmaceuticals)<\/strong><span><strong>.<\/strong>&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>What to know more? Request for sample @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lichen-planus-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Lichen Planus Oral Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The Lichen Planus market report<\/span><span> covers current treatment practices, emerging drugs, individual therapies&#8217;,&nbsp; Lichen Planus market share, and current and forecasted Lichen Planus market size from 2017 to 2030, segmented by seven major markets.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Lichen Planus: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Lichen Planus is a chronic, immune-mediated mucocutaneous disease that can affect mucosal surfaces, particularly those that line the mouth. It can affect the skin (cutaneous lichen planus)<\/span><span>, <\/span><span>the mouth (oral lichen planus), the genitalia (penile or vulvar lichen planus), the scalp (lichen planopilaris), the nails, or the esophagus. Reticular, atrophic\/erosive, and plaque-like oral Lichen Planus are some of the different types of oral Lichen Planus that can arise alone or in combination.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Lichen Planus Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The Lichen Planus report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Lichen Planus Total Prevalent Population&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Lichen Planus Type-SPecific Prevalent Population<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Lichen Planus Gender-Specific Prevalent Population<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Lichen Planus Diagnosed and Treatable Cases<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Lichen Planus Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>There is no cure for Lichen Planus and the current therapeutic market is mostly based on symptom relief and scar reduction from erosive lesions. The current treatment for Lichen Planus includes <\/span><span>Antihistamines, Topical and Oral Corticosteroids,<\/span><span> and <\/span><span>Light therapy.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get complete information on lichen planus treatment guidelines @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lichen-planus-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Lichen Planus Management<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Lichen Planus Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The total Lichen Planus market size will comprise both the market size of forthcoming therapies such as&nbsp; <\/span><span>Rivelin-clobetasoL, Valchlor (mechlorethamine), KPL-716, <\/span><span>and others <\/span><span>and the market size of current Lichen Planus treatment regimens in the 7MM.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Lichen Planus Emerging Drugs and Major Companies<\/strong><span>&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Rivelin-clobetasoL: AFYX Therapeutics<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>AIN457 (Cosentyx): Novartis<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Valchlor (mechlorethamine): Actellion<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>KPL-716: Kiniksa Pharmaceuticals<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><span>&nbsp;<\/span><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"66\" \/>\n<col width=\"558\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Lichen Planus: Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disease Background and Overview: Lichen Planus&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Lichen Planus Epidemiology and Patient Population<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Lichen Planus: Country-Wise Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Lichen Planus Treatments &amp; Medical Practices<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Lichen Planus Emerging Therapies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Lichen Planus: Market Size<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Lichen Planus<\/span><span>7MM: Country-Wise Market Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Lichen Planus Market Drivers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Lichen Planus Market Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Report Methodology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DelveInsight Capabilities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/oral-mucositis-om-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Oral Mucositis Market<\/a><\/strong><span>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive historical and forecast analysis of <\/span><span>Oral Mucositis<\/span><span> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><span><strong>Access Pharmaceuticals, Camurus, Innovation Pharmaceuticals, BrainCool, NeoMedLight, Soligenix,<\/strong>&nbsp;<\/span><span>among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=lichen-planus-treatment-market-to-derive-enormous-growth-from-the-expected-launch-of-emerging-therapies-in-the-forecast-period-202030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lichen-planus-treatment-market-to-derive-enormous-growth-from-the-expected-launch-of-emerging-therapies-in-the-forecast-period-202030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lichen Planus Market The total Lichen Planus market size will include both the market size of upcoming therapies like Rivelin-clobetasoL, Valchlor (mechlorethamine), KPL-716, and others, as well as the market size of current Lichen Planus treatment regimens in the 7MM. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/lichen-planus-treatment-market-to-derive-enormous-growth-from-the-expected-launch-of-emerging-therapies-in-the-forecast-period-202030_554526.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-554526","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/554526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=554526"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/554526\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=554526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=554526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=554526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}